RE:RE:RE:RE:All time low!Nothing has changed. We still need to hear from the company about the status of the BTD application. But we are are very close to definitive "best in class" data.
What genuine investor would be talking about selling off our IP when we are so close? They have probably already raised enough money to get us over the hump. You don't sell off your seed stock unless you're giving up on a future harvest..
N0taP00p wrote: @gebremeskel: What changed from October when you said it's hard to interpret the BTD submission timeline based on the last NR? A small cash infusion would help, certainly, but only if the timeline is not too far out. Right? Maybe you're thinking it's a short window to submission and approval. If so, it's an assumption but still a risk. Calling out a risk (which you also implied) is not bashing, is it?
gebremeskel wrote: The soft bashers are getting bolder. They think they smell blood but Theralase is not actually wounded. We're very close to undeniable success in this trial. A small cash infusion should be enough to bring us over the line. We are on the verge of proving this treatment is the best option available for bcg unresponsive NMIBC and there is much more to follow.